SEOUL, Feb. 22 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Tuesday that a high-concentration version of its autoimmune disease biosimilar Yuflyma has won approval from European drug authorities. The European Medicines Agency (EMA) gave the green light to Celltrion’s application to sell Yuflyma — a biosimilar referencing blockbuster drug Humira by AbbVie [...]
SEOUL, Feb. 14 (Korea Bizwire) — Sales of the biosimilar Remsima by Celltrion Inc. reached an all-time high last year in the United States, the company said Monday. Sales of the biosimilar drug to treat autoimmune diseases jumped 13 percent on-year to US$385 million in 2021, Celltrion Healthcare said, citing industry data. Remsima references Janssen [...]
SEOUL, Dec. 30 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Thursday its new biosimilar of the arthritis drug Humira has won approval from Canadian authorities. Yuflyma, an adalimumab biosimilar with a high concentration, is used to treat patients with rheumatoid arthritis, psoriasis and inflammatory diseases. Yuflyma requires only half the solution administered [...]
SEOUL, June 15 (Korea Bizwire) — South Korean pharmaceutical firm Samsung Bioepis Co. said Monday that it has won approvals in major countries to conduct clinical trials for its new ophthalmology biosimilar candidate. SB15 is a biosimilar candidate referencing Regeneron Pharmaceuticals Inc.’s Eylea, a blockbuster therapy to treat age-related (wet) macular degeneration (AMD). It is [...]
SEOUL, June 10 (Korea Bizwire) — An affiliate of South Korean biopharmaceutical firm Celltrion Inc. said Wednesday that it will begin a study on the treatment efficacy of its biosimilar Remsima on the novel coronavirus. Celltrion Healthcare, which handles Celltrion’s overseas business, said the trial study of Remsima, a biosimilar drug to treat autoimmune diseases, [...]
SEOUL, April 16 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Bioepis Co. said Thursday its breast cancer biosimilar Ontruzant is now available in the United States. Global health care company MSD has begun distributing the biosimilar that references Switzerland-based Roche Holding’s Herceptin, also known as Trastuzumab, in the world’s largest pharmaceutical market, Samsung Bioepis [...]
SEOUL, Nov. 16 (Korea Bizwire) – Technology Licensing Offices at hospitals, universities and research labs had successfully inked 405 technology transfer deals with businesses as of October, the Ministry of Health and Welfare revealed on November 15. Technology Licensing Offices, commonly referred to as TLOs, are organizations set up as intermediaries that serve as the [...]
SEOUL, Aug. 8 (Korea Bizwire) – Samsung BioLogics Co., a biosimilar firm affiliated with Samsung Group, will apply for preliminary approval this week for its initial public offering (IPO), estimated at around 3 trillion won (US$2.68 billion), South Korea’s bourse said Monday. The firm, one of the world’s largest manufacturers of biosimilar medicine, plans to [...]
SEOUL, June 9 (Korea Bizwire) – Samsung Bioepis announced the results of clinical studies on its three biosimilars on June 8, 2016, at the Annual European Congress of Rheumatology (EULAR 2016 London) which is being held in London until June 11. The three biosimilars that are currently sold in Korea and Europe include BRENZYS (Benepali in [...]
SEOUL, May 24 (Korea Bizwire) – Recent anticipation predicts that Korea’s biosimilar market will grow to a 150-billion-won industry by 2019. According to the Korea Pharmaceutical Manufacturers Association (KPMA), the industry, which was valued at 80 billion won in 2013, will grow to a 150 billion won market by 2019. The government’s active policy towards biosimilars, [...]